Viebig, Tom; Mische, Harald; Cole, Miranda; De Coninck, Raphaël; Sauri Romero, Lluís; Henschen, Horst

21 May 2021 Webinar

Excessive prices in the pharmaceutical sector in the EU: The Aspen Decision

Law & Economics Webinar organised by Concurrences, in partnership with Covington & Burling and CRA, with Miranda Cole (Partner, Covington & Burling), Raphaël de Coninck (Vice President, CRA), Horst Henschen (Of Counsel, Covington & Burling), Harald Mische (Case Handler - Antitrust: Pharma and Health services, DG COMP), Lluís Sauri Romero (Head of Unit - CET, DG COMP) and Tom Viebig (Case Handler - Antitrust: Pharma and Health services, DG COMP).

Audio
Presentations
21 May 2021 - PDF - 6.2 MiB
Synthesis
21 June 2021 - PDF - 1 MiB
Transcript
23 June 2021 - PDF - 658.1 KiB

KEYWORDS

– PPT Presentations: Available for Concurrences+ subscribers (see above)

– Video: Available for Concurrences+ subscribers (see below)

– Audio: Available for Concurrences+ subscribers (see above)

– Synthesis: Available for Concurrences+ subscribers (see above)

– Transcript: Available for Concurrences+ subscribers (see above)

– Concurrences Related Articles (Click Read More below and see page’s bottom)

Check the Upcoming Conferences section for the next webinars.

SYNTHESIS

Miranda Cole introduced the panel, mentioning that the purpose of the discussion is not to engage in an autopsy of the decision, but rather to understand its implications for the future. It will also be interesting to put the decision back into the context of other recent excessive pricing cases whether it be Pfizer/Flynn, which is now referred to the U.K. Competition and Markets Authority; the Italian approach to Aspen’s conduct as well; the Danish decision in CD Pharma; and Gazprom, which is the only other relatively recent excessive pricing case from the Commission. One should also go back to the Commission’s 2020 Communication on Pharmaceutical Strategy for Europe, which aims at ensuring access to affordable medicines for patients and supporting competitiveness, innovation, and sustainability of the EU pharmaceutical industry.

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

UK Competition Authority The UK Competition Authority secures legally binding commitments from a manufacturer of six cancer drugs to maintain reduced prices for 10 years (Aspen)
27 April 2022

CMA helps NHS secure price and supply commitment for cancer drugs* The CMA has worked to ensure that pharmaceutical company Aspen’s commitments to reduce prices for life-saving cancer medicines can be enforced in the UK following its exit from the European Union. The European Commission (...)
Donald Slater The EU Commission accepts commitments from a pharmaceutical company to address excessive pricing (Aspen)
10 February 2021

On 10 February 2021, the European Commission accepted commitments from Aspen under Article 9(1) of Regulation 1/2003, concluding a three year investigation into suspected excessive pricing practices affecting six critical cancer medicines. What you need to know - key takeaways The (...)
European Commission The EU Commission accepts commitments made by a pharmaceutical company to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns (Aspen)
10 February 2021

Antitrust: Commission accepts commitments by Aspen to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns* The European Commission has made commitments offered by Aspen legally binding under EU antitrust rules. Aspen has to reduce its prices in (...)
Alain Ronzano Excessive prices: The European Commission accepts and makes binding the commitments of one pharmaceutical company to reduce the prices of six anti-cancer drugs by 73% for ten years, and sends a strong signal to other pharmaceutical companies about excessive pricing practices (Aspen)
10 February 2021

See also, Law & Economics Webinar organised by Concurrences "Excessive prices in the pharmaceutical sector in the EU: The Aspen Decision", in partnership with Covington & Burling and CRA, with Miranda Cole (Partner, Covington & Burling), Raphaël de Coninck (Vice President, CRA), (...)
Samuel Hall The EU Commission accepts a commitment to reduce the price of six cancer medicines by 73% in an excessive pricing case in the pharmaceutical industry (Aspen)
10 February 2021

On 10 February 2021, the Commission announced that it had accepted a series of pricing and supply commitments from Aspen, thereby bringing an end to its investigation into whether Aspen had infringed Article 102 TFEU by charging excessive prices for six off-patent cancer medicines. Having (...)
Kyriakos Fountoukakos, Max Kaufman, Kristien Geeurickx, Agathe Célarié The EU Commission accepts the commitment offered by a pharmaceutical company to reduce drug prices by 73% (Aspen)
10 February 2021

“When the price of a drug suddenly goes up by several hundred percent, this is something the Commission may look at” Commissioner Vestager said when opening a formal investigation into Aspen’s alleged excessive pricing conduct in May 2017. On 10 February 2021, the EU Commission (Commission) (...)
Marie Cartapanis Excessive pricing: The European Commission accepts commitments of a company to reduce prices in cancer drug sector (Aspen)
10 February 2021

See also, Law & Economics Webinar organised by Concurrences "Excessive prices in the pharmaceutical sector in the EU: The Aspen Decision", in partnership with Covington & Burling and CRA, with Miranda Cole (Partner, Covington & Burling), Raphaël de Coninck (Vice President, CRA), (...)
Michael Clancy, Samuel Hall The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen)
10 February 2021

In February 2021, the European Commission’s (“Commission”) long-running excessive pricing case against Aspen was brought to a close, with Aspen accepting a series of forward-looking pricing and supply commitments, but avoiding any fines or requirements to repay all of the higher prices charged (...)
Hendrik Viaene, Karolien Van der Putten The EU Commission accepts commitments by a drug manufacturer to reduce prices by 73% in an excessive pricing case (Aspen)
10 February 2021

On 10 February 2021, the EC concluded its first excessive pricing investigation in the healthcare sector by accepting commitments from Aspen Pharmacare Holdings Ltd and Aspen Pharma Ireland Limited (collectively, Aspen) (Decision C (2021) 72 final in Case AT.40394, Aspen). The decision (...)
European Commission The EU Commission invites comments on a pharmaceutical company’s proposed commitment to reduce the price by 73% for six off-patent cancer medicines to address excessive pricing concerns (Aspen)
14 July 2020

Antitrust: Commission seeks feedback on commitments offered by Aspen to reduce prices for six off-patent cancer medicines by 73% to address Commission’s concerns over excessive pricing* The European Commission invites comments from all interested parties on commitments offered by Aspen to (...)
Eugenia Caracciolo The EU Commission invites parties to submit comments regarding a pharma company and its excessive pricing (Aspen)
14 July 2020

On 14 July 2020, the Commission invited interested parties to submit comments on the commitments offered by global pharma company Aspen to address competition concerns in relation to Aspen’s excessive pricing for six critical off-patent cancer medicines in several national markets (excluding (...)
Peter L’Ecluse, Catherine Longeval, Koen T’Syen The EU Commission starts a market test on the proposed commitments offered by a pharmaceutical company to address the Commission’s concerns over excessive pricing on a range of off-patent cancer medicines (Aspen)
14 July 2020

Today, the European Commission (the Commission) started a market test inviting comments from interested parties on commitments offered by Aspen Pharmacare Holdings (Aspen) to address the Commission’s concerns over excessive pricing for a range of off-patent cancer medicines (see, attached (...)
Bertold Bär-Bouyssière, Alina Lacatus, Jacob Borum, Darach Connolly The EU Commission invites comments from all interested parties on commitments offered by pharmaceutical company to address the Commission’s concerns over excessive pricing (Aspen)
14 July 2020

Aspen: Quick Fix But Missed Opportunity* What are commitments? The recent effort by the Commission to settle the Aspen case suggests that commitment decisions are the preferred route to settle complex excessive pricing cases at EU-level. Previous commitment cases where high prices have been (...)
Frédéric Marty Exploitative abuse: The European Commission initiates a market test of commitments proposed by a pharmaceutical company to address its competition concerns about possible excessive prices for anti-cancer drugs (Aspen)
14 July 2020

The Commission is launching a market test to gather the views of interested parties onAspen ’s proposed commitments to address competition concerns relating to its pricing practices on a number of cancer drugs. Pending a comment on the substance of the case - the Commission is only at the (...)
Stamatis Drakakakis, Argyris Papaefthymiou, Ellie Gavriilidou The EU Commission starts a market test inviting comments from interested parties on commitments offered by a pharmaceutical company that had abused its dominant position (Aspen)
14 July 2020

On 14 July 2020 the European Commission started a market test inviting comments from interested parties on commitments offered by Aspen Pharmacare Holdings. The Commission had opened an investigation in May 2017 over concerns that Aspen had abused its dominant position in a range of national (...)
European Commission The EU Commission opens formal investigation into a pharmaceutical company for excessive pricing practices (Aspen Pharma)
15 May 2017

Antitrust: Commission opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines* The European Commission has opened a formal investigation into concerns that Aspen Pharma has engaged in excessive pricing concerning five life-saving cancer medicines. The Commission (...)

Access to this article is restricted to subscribers

Read one article for free

Subscribe!